Improving Early Recognition of Creutzfeldt-Jakob Disease Mimics
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 21, 2022
- Accepted September 15, 2022
- First Published October 12, 2022.
Article Versions
- Previous version (October 12, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Evelyn B. Lazar, MD,
- Amanda L. Porter, MD,
- Christian C. Prusinski, DO,
- S. Richard Dunham, MD,
- A. Sebastian Lopez-Chiriboga, MD,
- M. Bakri Hammami, MD,
- Divyanshu Dubey, MD and
- Gregory S. Day, MD
- Evelyn B. Lazar, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Amanda L. Porter, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Christian C. Prusinski, DO,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- S. Richard Dunham, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NeuroNEXT, Grant 5 U24 NS107198, Fellow 2019- 2021
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- A. Sebastian Lopez-Chiriboga, MD,
Horizon scientific advisory board Genentech scientific advisory board
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- M. Bakri Hammami, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Divyanshu Dubey, MD and
None
Dr. Dubey has consulted for UCB, Immunovant, Argenx, Arialys and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.
None
Dr. Dubey is on the editorial board of Journal of Clinical Medicine.
Dr. Dubey has patent pending for Klech like protein 11, caveolae associated protein 4 and Leucine zipper 4 as a marker of neurological autoimmunity and germ cell tumors.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory S. Day, MD
None
NONE
Continuing Education Company, Honoraria + travel for CME activities Eli Lilly, reimbursement for travel to speak at an academic seminar concerning advantages of early diagnosis in AD
1. DynaMed, EBSCO; ad-hoc Dementia Topic Editor for online evidence-based medicine resource; 2016-ongoing. 2. Associate Editor, Journal of Alzheimer's Disease 3. Level of Evidence Rater, Neurology
NONE
NONE
NONE
1. Parabon Nanolabs, Inc (advice / support on NIH-funded project).
NONE
NONE
NONE
1. Biogen: Involved in clinical trials of anti-amyloid agents (no direct payments; research agreement between sponsor and institution). 2. Eli Lilly: Money received by institution for participation in educational seminar on advantages of early diagnosis of AD Research Support, Government Entities: 1. NIH/NIA: K23AG064029, PI, 2019-2024 2. NIH/NIA: U01AG057195, site-PI, 2021- 3. NIH/NIA: U19AG032438, site-PI, 2021-
NONE
NONE
1. Chan Zuckerberg Foundation (Neurodegenerative Challenge Network), CS-0000000472, Clinical PI, 2019-2022 2. Alzheimer's Association (Grant to promote diverse recruitment in LEADS; PI, 2021-22)
NONE
NONE
NONE
NONE
1) Hold stocks (>$10,000) in ANI Pharmaceuticals (a generic pharmaceutical company; 2015 onward). 2) Parabon Nanolabs, Inc (stock options).
1. Barrow Law, consultant concerning legal proceedings, 2018- 2021
- Department of Neurology (E.B.L., A.L.P., C.C.P., A.S.L.-C., G.S.D.), Mayo Clinic in Florida, Jacksonville, FL; Department of Neurology (S.R.D.), Washington University School of Medicine, Saint Louis, MO; Department of Laboratory Medicine and Pathology (M.B.H., D.D.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. Day day.gregory{at}mayo.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
RELATED MULTIMEDIA
Podcast
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.